Drug Profile
Denosumab - Amgen
Alternative Names: AMG-162; PRALIA; Prolia; Ranmark; XgevaLatest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; Celgene Corporation; Daiichi Sankyo Company; European Thoracic Oncology Platform; GlaxoSmithKline; GSK; Jules Bordet Institute; Melbourne Health; University Health Network; University Hospital Ghent
- Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bone disorders; Bone metastases; Corticosteroid-induced osteoporosis; Giant cell tumour of bone; Male osteoporosis; Malignant hypercalcaemia; Osteoporosis; Postmenopausal osteoporosis; Rheumatoid arthritis
- Phase III Breast cancer; Non-small cell lung cancer; Osteogenesis imperfecta
- Phase II Malignant melanoma; Osteoarthritis
- No development reported Multiple myeloma
Most Recent Events
- 01 Jan 2024 China includes Skeletal-Related Events into the latest National Reimbursement Drug List 2024 (NRDL)
- 20 Dec 2023 Amgen completes a phase III trial in Corticosteroid-induced osteoporosis (In adolescents, In children) in USA, Australia, Belgium, Bulgaria, Canada, India, Italy, Mexico, Peru, Russia, Turkey, Colombia and Ukraine (SC) (NCT03164928)
- 05 Dec 2023 Efficacy data from phase II GeparX trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)